US92337R1014
© Globe Newswire
26.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
News Preview
Vera Therapeutics appoints veteran biotech executive
James R. Meyers to its Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Vera Therapeutics' management team will present and participate in one-on-one meetings at upcoming investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
News Preview
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
07.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock u...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
06.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
News Preview
BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simult...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
VERA
LISTED
NASDAQ
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
News Preview
Vera Therapeutics to host an investor call and Webcast to provide an ORIGIN 3 update on November 6, 2025 at 4:30 pm ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
News Preview
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 135,100 shares of Class A common stock and restricted stock u...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 85,000 shares of Class A common stock and restricted stock units (RSUs) unde...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate at Upcoming Investor Conferences
News Preview
BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlyi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
10.07.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common st...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common sto...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
News Preview
BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common s...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the fourth quarter and full y...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 35,250 shares of Class A common stock and restricted stock units (RSUs) for 17,625 shares of Class A common...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
News Preview
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next gene...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A commo...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.11.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate at Upcoming Investor Conferences
News Preview
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate at Upcoming Investor Conferences
News Preview
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
News Preview
BRISBANE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the third quarter ended Septe...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
News Preview
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A comm...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
News Preview
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to is...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
News Preview
BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropat...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A common stock and restricted stock units (RSUs) for 62,500 shares of Class A common...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 33,000 shares of Class A common stock and restricted stock units (RSUs) for 16,500 shares of Class A common s...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
News Preview
BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.07.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 160,000 shares of Class A common stock to David Johnson, Vera’s new Chief Operatin...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
VERA
LISTED
NASDAQ
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
News Preview
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in the Goldman Sachs 45th...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.05.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
News Preview
BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobuli...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
News Preview
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
